NEW YORK (GenomeWeb News) – Trovagene reported after the close of the market Thursday that its third quarter revenues fell to $44,000 from $211,000 year over year.

All of the firm's revenues were derived from royalties, a company official said on a conference call following the release of the results.

Trovagene posted a net loss of $4.4 million, or $.25 per share, for the three month period ended Sept. 30, compared to a net loss of $660,000, or $.05 per share, for Q3 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.